Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
NASDAQ
Unprofitable
Unprofitable
226M
Biotechnology
Next Earning date - 13 Aug 2025
226M
Biotechnology
Next Earning date - 13 Aug 2025
Relative Strenght
96Volume Buzz
187%Earning Acce
NoDist 52w H.
23%